ArticleFrontiers in genetics2019
A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide.
Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Reprogramming temozolomide response in glioblastoma through regulated and immunogenic cell death modalities.Cell death discovery · 2026Review
- The Clinical Utility of Cell-Free DNA in Brain Tumor Management: A Comprehensive Review.Journal of molecular neuroscience : MN · 2025Review
- Review
- Comparative analysis of pyrosequencing and next-generation sequencing for assessing MGMT methylation in glioma patients.Journal of neuro-oncology · 2025Article
- Unravelling the mosaic: Epigenetic diversity in glioblastoma.Molecular oncology · 2024Review
- Changes in cortical manifold structure following stroke and its relation to behavioral recovery in the male macaque.Nature communications · 2024Article
- Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.CNS neuroscience & therapeutics · 2024Article
- Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics.Clinical epigenetics · 2022Article
- Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial.Frontiers in genetics · 2022Article
- Epigenomics and immunotherapeutic advances in pediatric brain tumors.NPJ precision oncology · 2021Review
- A New Epigenetic Model to Stratify Glioma Patients According to Their Immunosuppressive State.Cells · 2021Article
- Predictive value of MGMT promoter methylation on the survival of TMZ treatedCancer biology & medicine · 2021Article
- DNA methylation analysis with methylation-sensitive high-resolution melting (MS-HRM) reveals gene panel for glioma characteristics.CNS neuroscience & therapeutics · 2020Article
- CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.Journal of cellular and molecular medicine · 2020Article
- Transcriptional Characteristics ofFrontiers in cell and developmental biology · 2020Article
- How DNA methylation affects the Warburg effect.International journal of biological sciences · 2020Review
- A Potential Mechanism of Temozolomide Resistance in Glioma-Ferroptosis.Frontiers in oncology · 2020Article
- Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma.Frontiers in pharmacology · 2020Article
- Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most malignant glioma, with a median overall survival (OS) of 14-16 months. Temozolomide (TMZ) is the first-line chemotherapy drug for glioma, but whether TMZ should be withheld from patients with GBMs that lack O6-methylguanine-DNA methyltransferase (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.